(Q46841926)

25 December 2017

title

Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition (English)

1 reference

25 December 2017

1 reference

9

Caroline Seynaeve

1 reference

25 December 2017

Alastair I Bartlett

1

1 reference

25 December 2017

Jane Starcyznski

2

1 reference

25 December 2017

Tammy Robson

3

1 reference

25 December 2017

Alex Maclellan

4

1 reference

25 December 2017

Fiona M Campbell

5

1 reference

25 December 2017

Cornelis J H van de Velde

6

1 reference

25 December 2017

Annette Hasenburg

7

1 reference

25 December 2017

Christos Markopoulos

8

1 reference

25 December 2017

Daniel Rea

10

1 reference

25 December 2017

John M S Bartlett

11

1 reference

25 December 2017

American Journal of Clinical Pathology

language of work or name

English

1 reference

inferred from

publication date

1 August 2011

1 reference

25 December 2017

American Journal of Clinical Pathology

published in

1 reference

25 December 2017

volume

136

1 reference

25 December 2017

issue

2

1 reference

25 December 2017

page(s)

266-274

1 reference

25 December 2017

HER2 testing in the UK: further update to recommendations

cites work

1 reference

https://api.crossref.org/works/10.1309%2FAJCP0EN6AQMWETZZ

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP0EN6AQMWETZZ

Best Practice No 176: Updated recommendations for HER2 testing in the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP0EN6AQMWETZZ

Recommendations for HER2 testing in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP0EN6AQMWETZZ

HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP0EN6AQMWETZZ

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP0EN6AQMWETZZ

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP0EN6AQMWETZZ

External quality assurance of HER2 FISH and ISH testing: three years of the UK national external quality assurance scheme

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP0EN6AQMWETZZ

The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP0EN6AQMWETZZ

Clone heterogeneity in diploid and aneuploid breast carcinomas as detected by FISH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP0EN6AQMWETZZ

Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP0EN6AQMWETZZ

Current perspectives on HER2 testing: a review of national testing guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP0EN6AQMWETZZ

HER2 testing recommendations in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP0EN6AQMWETZZ

Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP0EN6AQMWETZZ

Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP0EN6AQMWETZZ

Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1309%2FAJCP0EN6AQMWETZZ

21 January 2018

Identifiers

DOI

10.1309/AJCP0EN6AQMWETZZ

1 reference

25 December 2017

1 reference

25 December 2017